antibody

Mouse Anti Human Synaptobrevin-2

MBS140315

0.02 mg

205 USD

monoclonal

mouse

nonconjugated

P3E5AT

western blot, ELISA, enzyme immunoassay

Antibody

Mouse Anti Human Synaptobrevin-2

Synaptobrevin-2

VAMP2 Antibody; Synaptobrevin-2, Mouse Anti Human; Vesicle-associated membrane protein 2; SYB2; VAMP-2; Synaptobrevin-2; VAMP2; FLJ11460

vesicle-associated membrane protein 2; Vesicle-associated membrane protein 2; vesicle-associated membrane protein 2; synaptobrevin 2; synaptobrevin-2; vesicle associated membrane protein 2; vesicle-associated membrane protein 2 (synaptobrevin 2); Synaptobrevin-2

VAMP2

VAMP2; VAMP2; SYB2; VAMP-2; SYB2; VAMP-2

VAMP2_HUMAN

Monoclonal

IgG1 heavy chain and kappa light chain

P3E5AT

Mouse

116

VAMP2 antibody was purified from mouse ascitic fluids by protein-G affinity chromatography.

1mg/ml containing PBS, pH-7.4, & 0.1% Sodium Azide.

For periods up to 1 month store at 4 degree C, for longer periods of time, store at -20 degree C. Prevent freeze thaw cycles. 12 months at -20 degree C. 1 month at 4 degree C.

ELISA (EIA), Western Blot (WB)

VAMP2 antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended dilution range for Western blot analysis is 1:1,000 ~ 3,000. Recommended starting dilution is 1:2,000.

Immunogen: Anti-human VAMP2 mAb is derived from hybridization of mouse SP2/O myeloma cells with spleen cells from BALB/c mice immunized with recombinant human VAMP2 amino acids 1-89 purified from E Coli.

MONOCLONAL/POLYCLONAL ANTIBODIES, MISCELLANEOUS ANTIBODIES; Monoclonal Antibodies

Introduction: Synaptobrevin 2 which is an 18 kDa integral membrane protein localized to the cytoplasmic surface of synaptic vesicle, consists of a proline-rich N-terminal region, a highly conserved hydrophilic domain, followed by a transmembrane anchor and a C-terminal. Synaptobrevin 2 is predominantly expressed in Langerhans islets and glomerular cells. The N-terminal domain of the protein (residues 1-89) forms a specific SNARE complex with the target membrane-associated t- or Q-SNAREs syntaxin 1 and SNAP-25.

172072620

NP_055047.2

NM_014232.2

12,663 Da

Acetylcholine Neurotransmitter Release Cycle Pathway 106525!!Clathrin Derived Vesicle Budding Pathway 119545!!Disease Pathway 530764!!Dopamine Neurotransmitter Release Cycle Pathway 106523!!Effects Of Botulinum Toxin Pathway 138028!!GABA Synthesis, Release, Reuptake And Degradation Pathway 187174!!Glutamate Neurotransmitter Release Cycle Pathway 106522!!Golgi Associated Vesicle Biogenesis Pathway 119546!!Insulin Signaling Pathway 198845!!Insulin Processing Pathway 105903

The protein encoded by this gene is a member of the vesicle-associated membrane protein (VAMP)/synaptobrevin family. Synaptobrevins/VAMPs, syntaxins, and the 25-kD synaptosomal-associated protein SNAP25 are the main components of a protein complex involved in the docking and/or fusion of synaptic vesicles with the presynaptic membrane. This gene is thought to participate in neurotransmitter release at a step between docking and fusion. The protein forms a stable complex with syntaxin, synaptosomal-associated protein, 25 kD, and synaptotagmin. It also forms a distinct complex with synaptophysin. It is a likely candidate gene for familial infantile myasthenia (FIMG) because of its map location and because it encodes a synaptic vesicle protein of the type that has been implicated in the pathogenesis of FIMG. [provided by RefSeq, Jul 2008]

0.02 mg

205 USD